Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

GeneDx Holdings (WGS) Other Operating Expenses: 2021-2024

Historic Other Operating Expenses for GeneDx Holdings (WGS) over the last 2 years, with Dec 2024 value amounting to -$785,000.

  • GeneDx Holdings' Other Operating Expenses rose 60.03% to -$785,000 in Q4 2024 from the same period last year, while for Dec 2024 it was -$3.4 million, marking a year-over-year increase of 52.83%. This contributed to the annual value of -$3.4 million for FY2024, which is 52.83% up from last year.
  • As of Q4 2024, GeneDx Holdings' Other Operating Expenses stood at -$785,000, which was down 1.42% from -$774,000 recorded in Q3 2024.
  • GeneDx Holdings' 5-year Other Operating Expenses high stood at -$718,000 for Q2 2023, and its period low was -$58.5 million during Q2 2021.
  • Moreover, its 3-year median value for Other Operating Expenses was -$1.3 million (2022), whereas its average is -$1.4 million.
  • As far as peak fluctuations go, GeneDx Holdings' Other Operating Expenses slumped by 64.64% in 2023, and later soared by 72.30% in 2024.
  • GeneDx Holdings' Other Operating Expenses (Quarterly) stood at -$58.5 million in 2021, then reached -$1.6 million in 2022, then fell by 22.75% to -$2.0 million in 2023, then spiked by 60.03% to -$785,000 in 2024.
  • Its Other Operating Expenses stands at -$785,000 for Q4 2024, versus -$774,000 for Q3 2024 and -$874,000 for Q2 2024.